Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study.

ABSTRACT:

Background

Human telomerase reverse transcriptase (hTERT) is an antigen that may represent a target for a novel anti-cancer strategy. A pilot, phase I study tested the safety and feasibility of a prime-boost immunization regimen based on V935, an adenoviral type 6 vector vaccine expressing a modified version of hTERT, administered alone or in combination with V934, a DNA plasmid that also expresses the same antigen and is delivered using the electroporation injection technique.

Methods

Treatments: Group #1 received two doses (low-dose: 0.5 × 10⁹ vg, and high-dose: 0.5 × 10¹¹ vg) of V935 followed by a 4-week observation period. Group #2 received three doses of V934-electroporation and two doses of V935 following a 4-week observation period. Doses were lo

SUBMITTER: Aurisicchio L 

PROVIDER: S-EPMC6993365 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature